Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Ipamorelin is a selective growth hormonereleasing peptide (GHRP) and ghrelin receptor agonist , developed to stimulate growth hormone (GH) release in a controlled and targeted fashion
BPC-157 is prohibited under WADA's S0 category
It plays a pivotal role in glucose metabolism and appetite regulation through multiple mechanisms: Enhances insulin secretion: GLP-1 stimulates pancreatic -cells to release insulin in a glucose-dependent manner Suppresses glucagon: Reduces hepatic glucose production Delays gastric emptying: Creates prolonged satiety Central nervous system effects: Acts on appetite centers in the brain to reduce hunger and food intake Protects pancreatic -cells: Promotes cell proliferation and inhibits apoptosis GLP-1 Receptor Agonists in Clinical Practice GLP-1 receptor agonists (GLP-1 RAs) are medications designed to mimic the action of endogenous GLP-1 but with enhanced pharmacokinetic properties
Every batch of Koi GHK-Cu is synthesized and lyophilized in the United States, then released against independent third-party laboratory (Freedom Diagnostics Testing) testing
DSIP + Ipamorelin Stack Protocol Dose: 200 mcg DSIP + 200 mcg Ipamorelin Timing: Both injected 30 minutes before bed Cycle: 4 to 8 weeks on, 2 to 4 weeks off Best for: Athletes, recovery-focused users, anti-aging protocols This is the sleep-and-recovery stack
